Can a simple pill protect cancer patients from Treatment's harsh side effects?
NCT ID NCT07418879
Summary
This study aims to see if giving a white blood cell booster drug (Leucogen) alongside a targeted cancer drug (pralsetinib) can prevent a common and serious side effect—low white blood cell counts—in patients with advanced lung cancer. It will enroll 25 adults with a specific genetic change (RET fusion) in their cancer who are starting this treatment for the first time. The main goal is to check if the added drug makes the cancer treatment safer and easier to tolerate over the first three months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.